# US 2016/0256458 A1 · Benzopiperazine compositions as bet bromodomain inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256458 A1
- Document ID: US20160256458A1
- Status: Published application
- Kind: A1
- Application number: 15/153,698
- Filed: 2016-05-12
- Published: 2016-09-08
- Earliest claimed: 2013-11-18
- Applicants: Forma Therapeutics, Inc.
- Inventors: Kenneth W. BAIR; Torsten HERBERTZ; Goss S. KAUFFMAN; Katherine J. KAYSER-BRICKER; George P. LUKE; Matthew W. MARTIN; David S. MILLAN; Shawn E.R. SCHILLER; Adam C. TALBOT; Mark J. TEBBE
- Web page: https://patentgrep.com/patent/US20160256458A1

## CPC

- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 241/42: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 241/50: with hetero atoms directly attached to ring nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 417/14: containing three or more hetero rings
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 495/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.

## Claims

### Claim 1

A method of treating or inhibiting a cancer associated with the activity of one or more BET-family bromodomains in a patient comprising administering to said patient in need thereof a therapeutically effective amount of the compound of Formulae (I), (II), (III), (IV), (V), or (VI):
wherein:
X is selected from N or CR3;
Y is selected from N or CR5;
Z is selected from N or CR6;
R1 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R2 is —C(O)(CRkRl)nO(CRkRl)mRd, —C(O)(CRkRl)nRe, —S(O)2(CRkRl)nRf, —(CRkRl)nRg, —C(O)(CRkRl)nNRaRg or —C(O)(CRkRl)nS(CRkRl)mRf;
R3 and R6 are each independently selected from hydrogen or halogen;
R4 is hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, heterocycloalkyl, heteroaryl, —NRaRb, —C(O)Rh, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, —C1-C4 alkyl(aryl), —C1-C4 alkyl(heteroaryl), or —C1-C4 alkyl(heterocycloalkyl), wherein the cycloalkyl, aryl, heterocycloalkyl, heteroaryl, and alkyl are optionally substituted with one or more R10;
R5 is hydrogen, halogen, C1-C6 alkyl, nitro, —NH2, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 aminoalkyl, C1-C6 aminoalkoxy, CN, C1-C6 alkoxy, —C(O)NRaRb, —NRaS(O)2Rb, —NRaC(O)Rb, —NRaC(O)ORb, —NRaC(O)NRbRc, C1-C6 haloalkyl, C1-C6haloalkoxy, —S(O)2NRaRb, or —S(O)2Ra;
R7 is —C(O)R8, —C(O)OR8, —C(O)NR8R9, or —S(O)2R8;
R8 and R9 are each independently hydrogen, —(CRkRl)mORa, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, —(CRkRl)nNRaC(O)ORb, and oxo, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra, Rb, and Rc are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, CN, —C(O)C1-C6 alkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Re is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, CN, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rf is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl and heterocycloalkyl are optionally substituted with one or more R12;
R8 is C1-C6 alkyl, C3-C7 cycloalkyl, —C1-C4 alkyl(C3-C7 cycloalkyl), aryl, —C1-C4 alkyl(aryl), heteroaryl, —C1-C4 alkyl(heteroaryl), heterocycloalkyl, or —C1-C4 alkyl(heterocycloalkyl), wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rh is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)nN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2; and
each q is independently at each occurrence 1, 2, 3 or 4;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
wherein:
Ar is C6-C10 aryl or heteroaryl;
R2 is —C(O)(CRkRl)nO(CRkRl)mRd, —C(O)(CRkRl)nRe, —S(O)2(CRkRl)nRf, —(CRkRl)nRg, —C(O)(CRkRl)nNRaRg or —C(O)(CRkRl)nS(CRkRl)mRf;
R8 is —(CRkRl)mORa, C1-C6 alkyl, or C3-C6 cycloalkyl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, CN, —C(O)C1-C6 alkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Re is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, CN, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rf is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
R8 is C1-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl, —C1-C4 alkyl(cycloalkyl), aryl, —C1-C4 alkyl(aryl), heteroaryl, —C1-C4 alkyl(heteroaryl), heterocycloalkyl, or —C1-C4 alkyl(heterocycloalkyl), wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)nN(C1-C6alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or
C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m and n is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one to three R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m and n is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5; or
wherein:
R10 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently hydrogen, C1-C6 alkyl, —C1-C4alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)nN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H) C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2; and
each q is independently at each occurrence 1, 2, 3 or 4;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer of the compound of Formulae (I), (II), (III), (IV), (V), or (VI);
wherein the cancer is selected from the group consisting of prostate, ovary, pancreas, esophagus, thyroid, bladder, bone, bile duct, testicle, uterus, head, neck, salivary gland, small cell ling cancer, non-small cell lung cancer, castration-resistant prostate cancer, glioblastoma, astrocytoma, mebulloblastoma, neuroblastoma, neurofibromatosis, merkel cell carcinoma, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, cholangiocarcinoma, PD-L1 positive tumors, and DNA mismatch repair deficient tumors.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering an additional therapeutic agent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the additional therapeutic agent is selected from the group consisting of cytotoxic agent, cisplatin, doxorubicin, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, the epothilones, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, Lonafarib, tipifarnib, 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile hydrochloride, (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo diazepine-7-carbonitrile, cetuximab, imatinib, interferon alfa-2b, Pegylated interferon alfa-2b, aromatase combinations, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, leucovorin, oxaliplatin, pentostatine, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide 17α-ethinyl estradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrol acetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, 17α-hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide acetate, flutamide, toremifene citrate, goserelin acetate, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, vinorelbine, anastrazole, letrozole, capecitabine, raloxifene, droloxafine, hexamethylmelamine, bevacizumab, trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, porfimer sodium, cetuximab, thioTEPA, altretamine, melphalan, fulvestrant, exemestane, rituximab, alemtuzumab, dexamethasone, bicalutamide, chlorambucil, and valrubicin.

### Claim 4 (depends on 2)

The method of claim 2, wherein the additional therapeutic agent is selected from the group consisting of an AKT inhibitor, alcohol dehydrogenase inhibitor, alkylating agent, all-trans retinoic acid, antiandrogen, Anti-human immunodeficiency virus monoclonal antibody, azacitidine, BCL2 inhibitor, BCL-XL inhibitor, BCR-ABL inhibitor, BTK inhibitor, BTK/LCK/LYN inhibitor, CDK1/2/4/6/7/9 inhibitor, CDK4/6 inhibitor, CDK9 inhibitor, CBP/p300 inhibitor, EGFR inhibitor, endothelin receptor antagonist, ERK inhibitor, farnesyltransferase inhibitor, FLT3 inhibitor, glucocorticoid receptor agonist, HDM2 inhibitor, histone deacetylase inhibitor, IKKb inhibitor, immunomodulatory drug (IMiD), ingenol, ionizing radiation, ITK inhibitor, JAK1/JAK2/JAK3/TYK2 inhibitor, MEK inhibitor, midostaurin, MTOR inhibitor, PI3 kinase inhibitor, dual PI3 kinase/MTOR inhibitor, proteasome inhibitor, protein kinase C agonist, SUV39H1 inhibitor, TRAIL, VEGFR2 inhibitor, Wnt/β-catenin signalling inhibitor, decitabine, and anti-CD20 monoclonal antibody.

### Claim 5 (depends on 2)

The method of claim 2, wherein the additional therapeutic agent is one or more immune check point inhibitors.

### Claim 6 (depends on 5)

The method of claim 5, wherein the immune check point inhibitor is selected from the group consisting of CTLA4 inhibitors Ipilimumab and Tremelimumab; PD1 inhibitors Pembrolizumab, and Nivolumab; PDL1 inhibitors Atezolizumab (formerly MPDL3280A), MEDI4736, Avelumab, and PDR001; 4-1BB ligand inhibitors Urelumab and PF 05082566; OX40 ligand inhibitor MEDI6469; GITR inhibitor TRX518; CD27 inhibitor Varlilumab; TNFRSF25-TL1A inhibitors; CD40 ligand inhibitor CP 870893; HVEM-LIGHT-LTA and HVEM-BTLA-CD160 inhibitors; LAG3 inhibitors BMS 986016; TIM3 inhibitors; Siglecs inhibitors; ICOS ligand inhibitors; B7-H3 inhibitor MGA271; B7-H4 inhibitors; VISTA inhibitors; HHLA2-TMIGD2 inhibitors; inhibitors of Butyrophilins; BTNL2 inhibitors; CD244-CD48 inhibitors; inhibitors of TIGIT and PVR family members; KIRs inhibitor Lirilumab; inhibitors of ILTs and LIRs; NKG2D and NKG2A inhibitor IPH2201; inhibitors of MICA and MICB; CD244 inhibitors; CSF1R inhibitor Emactuzumab; IDO inhibitor INCB024360; TGFβ inhibitor Galunisertib; Adenosine-CD39-CD73 inhibitors; CXCR4-CXCL12 inhibitors Ulocuplumab and BKT140; Phosphatidylserine inhibitors Bavituximab; SIRPA-CD47 inhibitor CC 90002; VEGF inhibitors Bevacizumab; and Neuropilin inhibitor MNRP1685A

### Claim 7

A method of treating or inhibiting an inflammatory condition associated with the activity of one or more BET-family bromodomains in a patient comprising administering to said patient in need thereof a therapeutically effective amount of a compound of Formulae (I), (II), (III), (IV), (V), or (VI):
wherein:
X is selected from N or CR3;
Y is selected from N or CR5;
Z is selected from N or CR6;
R1 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R2 is —C(O)(CRkRl)nO(CRkRl)mRd, —C(O)(CRkRl)nRe, —S(O)2(CRkRl)nRf, —(CRkRl)nRg, —C(O)(CRkRl)nNRaRg or —C(O)(CRkRl)nS(CRkRl)mRf;
R3 and R6 are each independently selected from hydrogen or halogen;
R4 is hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, heterocycloalkyl, heteroaryl, —NRaRb, —C(O)Rh, —ORh, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, —C1-C4 alkyl(aryl), —C1-C4 alkyl(heteroaryl), or —C1-C4 alkyl(heterocycloalkyl), wherein the cycloalkyl, aryl, heterocycloalkyl, heteroaryl, and alkyl are optionally substituted with one or more R10;
R5 is hydrogen, halogen, C1-C6 alkyl, nitro, —NH2, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 aminoalkyl, C1-C6 aminoalkoxy, CN, C1-C6 alkoxy, —C(O)NRaRb, —NRaS(O)2Rb, —NRaC(O)Rb, —NRaC(O)ORb, —NRaC(O)NRbRc, C1-C6 haloalkyl, C1-C6 haloalkoxy, —S(O)2NRaRb, or —S(O)2Ra;
R7 is —C(O)R8, —C(O)OR8, —C(O)NR8R9, or —S(O)2R8;
R8 and R9 are each independently hydrogen, —(CRkRl)mORa, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, —(CRkRl)nNRaC(O)ORb, and oxo, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra, Rb, and Rc are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, CN, —C(O)C1-C6 alkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Re is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, CN, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rf is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl and heterocycloalkyl are optionally substituted with one or more R12;
Rg is C1-C6 alkyl, C3-C7 cycloalkyl, —C1-C4 alkyl(C3-C7 cycloalkyl), aryl, —C1-C4 alkyl(aryl), heteroaryl, —C1-C4 alkyl(heteroaryl), heterocycloalkyl, or —C1-C4 alkyl(heterocycloalkyl), wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rh is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2; and
each q is independently at each occurrence 1, 2, 3 or 4;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
wherein:
Ar is C6-C10 aryl or heteroaryl;
R2 is —C(O)(CRkRl)nO(CRkRl)mRd, —C(O)(CRkRl)nRe, —S(O)2(CRkRl)nRf, —(CRkRl)nRg, —C(O)(CRkRl)nNRaRg or —C(O)(CRkRl)nS(CRkRl)mRf;
R8 is —(CRkRl)mORa, C1-C6 alkyl, or C3-C6 cycloalkyl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C6 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, CN, —C(O)C1-C6 alkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Re is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, CN, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rf is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rg is C1-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl, —C1-C4 alkyl(cycloalkyl), aryl, —C1-C4 alkyl(aryl), heteroaryl, —C1-C4 alkyl(heteroaryl), heterocycloalkyl, or —C1-C4 alkyl(heterocycloalkyl), wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or
C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m and n is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one to three R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m and n is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5; or
wherein:
R10 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently hydrogen, C1-C6 alkyl, —C1-C4alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H) C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2; and
each q is independently at each occurrence 1, 2, 3 or 4;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer of the compound of Fomulae (I), (II), (III) or (IV);
wherein the cancer is selected from the group consisting of prostate, ovary, pancreas, esophagus, thyroid, bladder, bone, bile duct, testicle, uterus, head, neck, salivary gland, small cell ling cancer, non-small cell lung cancer, castration-resistant prostate cancer, glioblastoma, astrocytoma, mebulloblastoma, neuroblastoma, neurofibromatosis, merkel cell carcinoma, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, cholangiocarcinoma, PD-L1 positive tumors, and DNA mismatch repair deficient tumors.
or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer of the compound of Formulae (I), (II), (III), (IV), (V), or (VI);
wherein the inflammatory disorder is periodontitis, psoriatic arthritis, ankylosing spondylitis, HIV-associated nephropathy, amyotrophic lateral sclerosis, systemic sclerosis, pulmonary arterial hypertension, acute allograft rejection, chronic organ transplant rejection, lupus nephritis, and severe celiac/coeliac disease.

### Claim 8 (depends on 7)

The method of claim 7, further comprising administering an additional therapeutic agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the additional therapeutic agent is selected from the group consisting of cytotoxic agent, cisplatin, doxorubicin, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, the epothilones, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, Lonafarib, tipifarnib, 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile hydrochloride, (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo diazepine-7-carbonitrile, cetuximab, imatinib, interferon alfa-2b, Pegylated interferon alfa-2b, aromatase combinations, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, leucovorin, oxaliplatin, pentostatine, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide 17α-ethinyl estradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrol acetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, 17α-hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide acetate, flutamide, toremifene citrate, goserelin acetate, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, vinorelbine, anastrazole, letrozole, capecitabine, raloxifene, droloxafine, hexamethylmelamine, bevacizumab, trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, porfimer sodium, cetuximab, thioTEPA, altretamine, melphalan, fulvestrant, exemestane, rituximab, alemtuzumab, dexamethasone, bicalutamide, chlorambucil, and valrubicin.

### Claim 10 (depends on 8)

The method of claim 8, wherein the additional therapeutic agent is selected from the group consisting of an AKT inhibitor, alcohol dehydrogenase inhibitor, alkylating agent, all-trans retinoic acid, antiandrogen, Anti-human immunodeficiency virus monoclonal antibody, azacitidine, BCL2 inhibitor, BCL-XL inhibitor, BCR-ABL inhibitor, BTK inhibitor, BTK/LCK/LYN inhibitor, CDK1/2/4/6/7/9 inhibitor, CDK4/6 inhibitor, CDK9 inhibitor, CBP/p300 inhibitor, EGFR inhibitor, endothelin receptor antagonist, ERK inhibitor, farnesyltransferase inhibitor, FLT3 inhibitor, glucocorticoid receptor agonist, HDM2 inhibitor, histone deacetylase inhibitor, IKKb inhibitor, immunomodulatory drug (IMiD), ingenol, ionizing radiation, ITK inhibitor, JAK1/JAK2/JAK3/TYK2 inhibitor, MEK inhibitor, midostaurin, MTOR inhibitor, PI3 kinase inhibitor, dual PI3 kinase/MTOR inhibitor, proteasome inhibitor, protein kinase C agonist, SUV39H1 inhibitor, TRAIL, VEGFR2 inhibitor, Wnt/β-catenin signalling inhibitor, decitabine, and anti-CD20 monoclonal antibody.

### Claim 11 (depends on 8)

The method of claim 8, wherein the additional therapeutic agent is one or more immune check point inhibitors.

### Claim 12 (depends on 11)

The method of claim 11, wherein the immune check point inhibitor is selected from the group consisting of CTLA4 inhibitors Ipilimumab and Tremelimumab; PD1 inhibitors Pembrolizumab, and Nivolumab; PDL1 inhibitors Atezolizumab (formerly MPDL3280A), MEDI4736, Avelumab, and PDR001; 4-1BB ligand inhibitors Urelumab and PF 05082566; OX40 ligand inhibitor MEDI6469; GITR inhibitor TRX518; CD27 inhibitor Varlilumab; TNFRSF25-TL1A inhibitors; CD40 ligand inhibitor CP 870893; HVEM-LIGHT-LTA and HVEM-BTLA-CD160 inhibitors; LAG3 inhibitors BMS 986016; TIM3 inhibitors; Siglecs inhibitors; ICOS ligand inhibitors; B7-H3 inhibitor MGA271; B7-H4 inhibitors; VISTA inhibitors; HHLA2-TMIGD2 inhibitors; inhibitors of Butyrophilins; BTNL2 inhibitors; CD244-CD48 inhibitors; inhibitors of TIGIT and PVR family members; KIRs inhibitor Lirilumab; inhibitors of ILTs and LIRs; NKG2D and NKG2A inhibitor IPH2201; inhibitors of MICA and MICB; CD244 inhibitors; CSF1R inhibitor Emactuzumab; IDO inhibitor INCB024360; TGFβ inhibitor Galunisertib; Adenosine-CD39-CD73 inhibitors; CXCR4-CXCL12 inhibitors Ulocuplumab and BKT140; Phosphatidylserine inhibitors Bavituximab; SIRPA-CD47 inhibitor CC 90002; VEGF inhibitors Bevacizumab; and Neuropilin inhibitor MNRP1685A

### Claim 13

A pharmaceutical composition comprising a compound of Formulae (I), (II), (III), (IV), (V), or (VI):
wherein:
X is selected from N or CR3;
Y is selected from N or CR5;
Z is selected from N or CR6;
R1 is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R2 is —C(O)(CRkRl)nO(CRkRl)mRd, —C(O)(CRkRl)nRe, —S(O)2(CRkRl)nRf, —(CRkRl)nRg, —C(O)(CRkRl)nNRaRg or —C(O)(CRkRl)nS(CRkRl)mRf;
R3 and R6 are each independently selected from hydrogen or halogen;
R4 is hydrogen, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, heterocycloalkyl, heteroaryl, —NRaRb, —C(O)Rh, —ORh, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, —C1-C4 alkyl(aryl), —C1-C4 alkyl(heteroaryl), or —C1-C4 alkyl(heterocycloalkyl), wherein the cycloalkyl, aryl, heterocycloalkyl, heteroaryl, and alkyl are optionally substituted with one or more R10;
R5 is hydrogen, halogen, C1-C6 alkyl, nitro, —NH2, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 aminoalkyl, C1-C6 aminoalkoxy, CN, C1-C6 alkoxy, —C(O)NRaRb, —NRaS(O)2Rb, —NRaC(O)Rb, —NRaC(O)ORb, —NRaC(O)NRbRc, C1-C6 haloalkyl, C1-C6haloalkoxy, —S(O)2NRaRb, or —S(O)2Ra;
R7 is —C(O)R8, —C(O)OR8, —C(O)NR8R9, or —S(O)2R8;
R8 and R9 are each independently hydrogen, —(CRkRl)mORa, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, —(CRkRl)nNRaC(O)ORb, and oxo, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra, Rb, and Rc are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, CN, —C(O)C1-C6 alkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Re is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, CN, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rf is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl and heterocycloalkyl are optionally substituted with one or more R12;
Rg is C1-C6 alkyl, C3-C7 cycloalkyl, —C1-C4 alkyl(C3-C7 cycloalkyl), aryl, —C1-C4 alkyl(aryl), heteroaryl, —C1-C4 alkyl(heteroaryl), heterocycloalkyl, or —C1-C4 alkyl(heterocycloalkyl), wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rh is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)nN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2; and
each q is independently at each occurrence 1, 2, 3 or 4;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
wherein:
Ar is C6-C10 aryl or heteroaryl;
R2 is —C(O)(CRkRl)nO(CRkRl)mRd, —C(O)(CRkRl)nRe, —S(O)2(CRkRl)nRf, —(CRkRl)nRg, —C(O)(CRkRl)nNRaRg or —C(O)(CRkRl)nS(CRkRl)mRf;
R8 is —(CRkRl)mORa, C1-C6 alkyl, or C3-C6 cycloalkyl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, CN, —C(O)C1-C6 alkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Re is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkoxy, CN, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rf is C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Rg is C1-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl, —C1-C4 alkyl(cycloalkyl), aryl, —C1-C4 alkyl(aryl), heteroaryl, —C1-C4 alkyl(heteroaryl), heterocycloalkyl, or —C1-C4 alkyl(heterocycloalkyl), wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or
C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m and n is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one to three R10;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m and n is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5;
wherein:
Ar is C6-C10 aryl or heteroaryl;
each R10 is independently at each occurrence selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently at each occurrence hydrogen, C1-C6 alkyl, —C1-C4 alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2;
each q is independently at each occurrence 1, 2, 3 or 4; and
s is 1, 2, 3, 4, or 5; or
wherein:
R10 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —ORi, —NRaRi, CN, oxo, —(CRkRl)nS(O)2Ri, —(CRkRl)nNRaS(O)2Ri, —(CRkRl)nS(O)2NRaRi, —(CRkRl)nNRaRiS(O)2NRaRi, —(CRkRl)nC(O)ORa, —(CRkRl)nC(O)Ri, —(CRkRl)nC(O)NRaRi, —(CRkRl)nRi, —(CRkRl)nNRaC(O)NRb, and —(CRkRl)nNRaC(O)ORb, wherein each alkyl is substituted with one or more R11; or
two R10 together when on adjacent carbons form an aryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R11; or two R10 together when on adjacent carbons form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxy, CN, C1-C6 hydroxyalkyl, —(CRkRl)mNH2, C1-C6 alkylamino, C1-C6 dialkylamino, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, —S(O)2Ra, —C(O)H, —NRaC(O)ORa, —NRaC(O)C1-C6 alkyl, or oxo;
or two R11 together can form a heterocycloalkyl ring;
Ra and Rb are each independently hydrogen, C1-C6 alkyl, —C1-C4alkyl(aryl), or aryl, wherein the alkyl and aryl are optionally substituted with one or more R10;
Rd is C1-C6 alkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R12;
Ri is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, —(CH2)qN(H)C1-C6 alkyl, —(CH2)qN(C1-C6 alkyl)2, —(CRkRl)mC3-C7 cycloalkyl, —(CRkRl)maryl, —(CRkRl)mheteroaryl, or —(CRkRl)mheterocycloalkyl, wherein alkyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more R11;
each R12 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H)C1-C6 alkyl, —O(CH2)qN(C1-C6alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —C(O)OC1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, or C1-C6 dialkylamino; or
two R12 together with the carbon to which they are attached can form a 4- to 6 membered heterospirocycle; or two R12 together when on adjacent carbons form a C4-C6 cycloalkyl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form an aryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heteroaryl optionally substituted with one or more R13; or two R12 together when on adjacent carbons form a heterocycloalkyl optionally substituted with one or more R13; or R12 with the carbon to which it is attached and the adjacent carbon form a C3 cycloalkyl optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxy, NO2, —NH2, CH2NH2, —(CH2)qN(C1-C6 alkyl)2, C1-C6 alkylamino, C1-C6 dialkylamino, —O(CH2)qN(H) C1-C6 alkyl, —O(CH2)qN(C1-C6 alkyl)2, aryl, heteroaryl, —NH-heteroaryl, —O-aryl, —S(O)p—C1-C6 alkyl, —S(O)p—N(H)C1-C6 alkyl, —S(O)p—N(C1-C6 alkyl)2, —C(O)C1-C6 alkyl, —NHC(O)(C1-C6 alkyl), or oxo, wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from consisting of C1-C6 alkyl, halogen, CN, C1-C6 alkoxy, hydroxy, NO2, —NH2, C1-C6 alkylamino, and C1-C6 dialkylamino;
Rk and Rl are each independently at each occurrence selected from H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, or halogen;
each m, n, and p is independently at each occurrence 0, 1, or 2; and
each q is independently at each occurrence 1, 2, 3 or 4;
provided that when m is 0, Rd is not C1-C6 alkoxy, C1-C6 haloalkoxy, or CN;
or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer of the compound of Fomulae (I), (II), (III) or (IV);
wherein the cancer is selected from the group consisting of prostate, ovary, pancreas, esophagus, thyroid, bladder, bone, bile duct, testicle, uterus, head, neck, salivary gland, small cell ling cancer, non-small cell lung cancer, castration-resistant prostate cancer, glioblastoma, astrocytoma, mebulloblastoma, neuroblastoma, neurofibromatosis, merkel cell carcinoma, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, cholangiocarcinoma, PD-L1 positive tumors, and DNA mismatch repair deficient tumors.
or a pharmaceutically acceptable salt, enantiomer, hydrate, solvate, isomer, or tautomer of the compound of Formulae (I), (II), (III), (IV), (V), or (VI);
a pharmaceutically acceptable carrier; and
one or more immune check point inhibitors.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the immune check point inhibitor is selected from the group consisting of CTLA4 inhibitors Ipilimumab and Tremelimumab; PD1 inhibitors Pembrolizumab, and Nivolumab; PDL1 inhibitors Atezolizumab (formerly MPDL3280A), MEDI4736, Avelumab, and PDR001; 4-1BB ligand inhibitors Urelumab and PF 05082566; OX40 ligand inhibitor MEDI6469; GITR inhibitor TRX518; CD27 inhibitor Varlilumab; TNFRSF25-TL1A inhibitors; CD40 ligand inhibitor CP 870893; HVEM-LIGHT-LTA and HVEM-BTLA-CD160 inhibitors; LAG3 inhibitors BMS 986016; TIM3 inhibitors; Siglecs inhibitors; ICOS ligand inhibitors; B7-H3 inhibitor MGA271; B7-H4 inhibitors; VISTA inhibitors; HHLA2-TMIGD2 inhibitors; inhibitors of Butyrophilins; BTNL2 inhibitors; CD244-CD48 inhibitors; inhibitors of TIGIT and PVR family members; KIRs inhibitor Lirilumab; inhibitors of ILTs and LIRs; NKG2D and NKG2A inhibitor IPH2201; inhibitors of MICA and MICB; CD244 inhibitors; CSF1R inhibitor Emactuzumab; IDO inhibitor INCB024360; TGFβ inhibitor Galunisertib; Adenosine-CD39-CD73 inhibitors; CXCR4-CXCL12 inhibitors Ulocuplumab and BKT140; Phosphatidylserine inhibitors Bavituximab; SIRPA-CD47 inhibitor CC 90002; VEGF inhibitors Bevacizumab; and Neuropilin inhibitor MNRP1685A.

### Claim 15 (depends on 13)

A method of inhibiting one or more of BET-family bromodomains in a patient comprising administering to the patient in need thereof an effective amount of the pharmaceutical composition of claim 13, or 15.
